All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.68 [0.22; 2.08]
COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.02; 49.67]
Mikhaylov, 2021 1.00 [0.02; 52.45]
NCT04422561 (Shouman), 2020 0.50 [0.01; 25.20]
PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16]
Seet 2021, 2021 1.00 [0.02; 50.64]
0.73 [0.28 ; 1.87 ] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID-PEP-Post exposure (Boulware), 2020, Mikhaylov, 2021, NCT04422561 (Shouman), 2020, PATCH-cohort 3 PreP (Abella), 2020, Seet 2021, 2021 6 0% 5,040 moderate not evaluable conversion to SARS-CoV- 2–positive status via NP swabdetailed results Abella, 2020 2.27 [1.09; 4.76]
2.27 [1.09 ; 4.76 ] Abella, 2020 1 0% 130 NA not evaluable hospitalizationdetailed results COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.06; 15.77]
Mikhaylov, 2021 0.23 [0.01; 5.48]
Rojas-Serrano, 2021 1.05 [0.02; 53.69]
0.61 [0.10 ; 3.85 ] COVID-PEP-Post exposure (Boulware), 2020, Mikhaylov, 2021, Rojas-Serrano, 2021 3 0% 998 low not evaluable new illness compatible with Covid-19 detailed results Ivercar-Tuc, 2021 0.13 [0.04; 0.47]
Mikhaylov, 2021 0.22 [0.04; 1.21]
NCT04422561 (Shouman), 2020 0.06 [0.03; 0.11]
Seet 2021, 2021 0.03 [0.02; 0.04]
0.06 [0.03 ; 0.14 ] Ivercar-Tuc, 2021, Mikhaylov, 2021, NCT04422561 (Shouman), 2020, Seet 2021, 2021 4 73% 1,824 serious not evaluable symptomatic Covid-19detailed results Barnabas RV, 2020 1.27 [0.79; 2.04]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.65 [0.18; 2.33]
COVID PREP HCQ (2x week, Rajasingham), 2020 1.18 [0.40; 3.50]
COVID-PEP-Post exposure (Boulware), 2020 0.84 [0.55; 1.27]
HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15]
Rojas-Serrano, 2021 0.16 [0.02; 1.38]
Seet (HCQ), 2021 0.91 [0.57; 1.47]
Syed, 2021 1.34 [0.66; 2.73]
0.92 [0.75 ; 1.13 ] Barnabas RV, 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, HERO-HCQ (Naggie), 2021, Rojas-Serrano, 2021, Seet (HCQ), 2021, Syed, 2021 8 0% 5,958 moderate not evaluable asymptomatic COVID casedetailed results EPICOS (Polo), 2022 0.96 [0.49; 1.90]
0.96 [0.49 ; 1.90 ] EPICOS (Polo), 2022 1 0% 454 NA not evaluable ICU admissiondetailed results Mikhaylov, 2021 1.00 [0.02; 52.45]
1.00 [0.02 ; 52.45 ] Mikhaylov, 2021 1 0% 50 NA not evaluable infection (PCR positive symptomatic or not)detailed results Barnabas RV, 2020 1.10 [0.73; 1.66]
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.73 [0.45; 1.19]
COVID PREP HCQ (2x week, Rajasingham), 2020 0.74 [0.45; 1.21]
COVID-PEP-Post exposure (Boulware), 2020 1.21 [0.49; 2.94]
EPICOS (Polo), 2022 0.87 [0.47; 1.62]
Grau-Pujol, 2020 0.42 [0.01; 12.67]
HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15]
PATCH-cohort 3 PreP (Abella), 2020 0.95 [0.23; 3.98]
Rojas-Serrano, 2021 0.16 [0.02; 1.38]
Seet (HCQ), 2021 0.41 [0.32; 0.53]
Syed, 2021 2.61 [1.05; 6.47]
0.81 [0.60 ; 1.10 ] Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, EPICOS (Polo), 2022, Grau-Pujol, 2020, HERO-HCQ (Naggie), 2021, PATCH-cohort 3 PreP (Abella), 2020, Rojas-Serrano, 2021, Seet (HCQ), 2021, Syed, 2021 12 67% 7,149 moderate low serious adverse eventsdetailed results Barnabas RV, 2020 1.04 [0.15; 7.40]
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.89 [0.44; 1.82]
NCT04422561 (Shouman), 2020 0.50 [0.01; 25.20]
PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16]
0.90 [0.47 ; 1.72 ] Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, NCT04422561 (Shouman), 2020, PATCH-cohort 3 PreP (Abella), 2020 4 0% 3,762 moderate not evaluable adverse eventsdetailed results Barnabas RV, 2020 1.58 [1.06; 2.37]
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 20.26 [15.67; 26.20]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.59 [0.44; 0.79]
COVID PREP HCQ (2x week, Rajasingham), 2020 2.02 [1.52; 2.70]
COVID-PEP-Post exposure (Boulware), 2020 3.32 [2.33; 4.72]
NCT04422561 (Shouman), 2020 11.52 [0.67; 197.97]
Rojas-Serrano, 2021 1.64 [0.78; 3.42]
2.76 [0.91 ; 8.39 ] Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, NCT04422561 (Shouman), 2020, Rojas-Serrano, 2021 7 98% 6,434 low not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 18:13 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290